Core Laboratories INC /DE/ 8-K filings

Core Laboratories Inc. announced second quarter 2026 financial results, showing sequential revenue improvement and a significant sequential increase in operating income, despite ongoing geopolitical conflicts impacting operations.

Core Laboratories shareholders approved the election of directors, the appointment of KPMG as auditor, and executive compensation at the 2026 Annual Meeting.

Core Laboratories Inc. reported first quarter 2026 financial results showing a sequential revenue decline and a significant drop in operating income, primarily attributed to geopolitical events in the Middle East and other global disruptions.

Core Laboratories Inc. revises its first quarter 2026 earnings guidance downward due to regional instability and operational disruptions in the Middle East.

Core Laboratories Inc. filed an amended report to correct a $4.2 million understatement of income tax expense for the quarter and year ended December 31, 2025, impacting net income and EPS.

Core Laboratories Inc. has amended its bylaws to reduce the shareholder voting threshold for significant corporate actions, including mergers and change in control transactions, from a 66-2/3% supermajority to a 50% plus one simple majority.

Core Laboratories Inc. reported sequential and year-over-year revenue growth for Q4 2025, driven by international demand, while also reducing net debt and repurchasing shares.

Core Laboratories Inc. reports sequential revenue growth, improved operating margins, significant debt reduction, and strategic acquisitions in Q3 2025, alongside a quarterly dividend.

Core Laboratories Inc. announced a renewed and expanded credit facility, alongside second-quarter 2025 financial results showing sequential revenue growth, improved profitability, and significant debt reduction.

Core Laboratories Inc. announced that its shareholders approved all three proposals at the Annual Meeting held on May 21, 2025, including the election of Class II Directors, ratification of KPMG LLP as independent auditor, and advisory approval of executive compensation.

Core Laboratories reports a 5% year-over-year decrease in revenue for Q1 2025, impacted by geopolitical factors, while maintaining its quarterly dividend.

Core Laboratories reports a slight increase in Q4 revenue and a significant reduction in debt leverage, alongside growth in full-year revenue and free cash flow.

Core Laboratories announced a solid third quarter in 2024, with revenue up 7% year-over-year and improved profitability, driven by international demand.

Core Laboratories announced its second quarter 2024 financial results, highlighting revenue of $130.6 million, improved operating income, and strong free cash flow.

Core Laboratories Inc. held its annual meeting on May 8, 2024, where shareholders approved the re-election of directors, the appointment of auditors, executive compensation, and an amendment to the long-term incentive plan.

Core Laboratories reported a slight increase in revenue for the first quarter of 2024, with a focus on debt reduction and strategic investments.

Core Laboratories has announced the resignation of its Vice President and Chief Accounting Officer, Kevin Daniels, and the appointment of Sow Hang Teo as his replacement, effective March 21, 2024.

Core Laboratories Inc. has amended its previously released financial results for the quarter and year ended December 31, 2023, due to an understatement of income tax expense, leading to a revision of its Return on Invested Capital (ROIC).

Core Laboratories announced its fourth quarter and full year 2023 financial results, highlighting modest revenue growth, debt reduction, and strategic investments in international markets.